Compare ELA & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELA | BNTC |
|---|---|---|
| Founded | 1965 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 365.3M | 313.9M |
| IPO Year | 1995 | 2020 |
| Metric | ELA | BNTC |
|---|---|---|
| Price | $12.06 | $8.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $25.00 | $24.33 |
| AVG Volume (30 Days) | 96.7K | ★ 187.5K |
| Earning Date | 11-04-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 115.38 | 6.67 |
| EPS | ★ 0.50 | N/A |
| Revenue | ★ $241,021,362.00 | N/A |
| Revenue This Year | $11.22 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $24.08 | ★ N/A |
| Revenue Growth | ★ 33.62 | N/A |
| 52 Week Low | $7.88 | $8.25 |
| 52 Week High | $29.68 | $16.76 |
| Indicator | ELA | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 36.94 | 28.71 |
| Support Level | $11.59 | N/A |
| Resistance Level | $14.91 | $14.09 |
| Average True Range (ATR) | 0.33 | 0.62 |
| MACD | 0.13 | -0.02 |
| Stochastic Oscillator | 38.13 | 4.83 |
Envela Corp is a provider of recycling and re-commerce services at the forefront of the circular economy. It operates through two segments, Consumer and Commercial Services. The Consumer segment, which generates key revenue for the company, predominantly buys to resell or recycle luxury hard assets like jewelry, diamonds, gemstones, fine watches, rare coins, and related collectibles, precious-metal bullion products, gold, silver, and other precious metals. The Commercial Services segment provides asset-disposition solutions to government agencies, middle-market firms, corporations, and other organizations.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.